A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women

被引:229
作者
Howard, AA
Arnsten, JH
Li, YT
Vlahov, D
Rich, JD
Schuman, P
Stone, VE
Smith, DK
Schoenbaum, EE
机构
[1] Montefiore Med Ctr, AIDS Res Program, Dept Epidemiol & Social Med, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[4] New York Acad Med, New York, NY USA
[5] Miriam Hosp, Dept Med, Providence, RI 02906 USA
[6] Brown Univ, Sch Med, Providence, RI 02912 USA
[7] Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA
[8] Mem Hosp Rhode Isl, Dept Med, Pawtucket, RI USA
[9] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA
关键词
adherence; compliance; electronic monitoring; women; drug users; viral load; antiretroviral therapy;
D O I
10.1097/00002030-200211080-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To examine the relationship between antiretroviral adherence and viral load, and to determine the predictors of adherence over time in HIV-infected women. Design: Prospective observational study. Methods: One-hundred sixty-one HIV-infected women who were taking antiretroviral therapy for a median of 3.0 years were recruited from the HIV Epidemiology Research Study, a multicenter cohort study of HIV infection in women. Antiretroviral adherence (percent of doses taken as prescribed) was measured over a 6-month period using MEMS caps. At baseline and follow-up, CD4 lymphocyte count and viral load were measured, and a standardized interview was administered to elicit medication history and drug use behaviors. To examine changes in adherence over time, the mean adherence to all antiretroviral agents was calculated for each monitored month. Results: Adherence varied significantly over time (P < 0.001), ranging from a mean of 64% in month 1 to 45% in month 6. Nearly one-fourth of the participants had a 10% or greater decrease in adherence between consecutive months. Virologic failure occurred in 17% of women with adherence of ≥ 88%, 28% of those with 45-87% adherence, 43% of those with 13-44% adherence, and 71% of those with ≤12% adherence. In multivariate analysis, factors predicting lower adherence included active drug use, alcohol use, more frequent antiretroviral dosing, shorter duration of antiretroviral use, younger age, and lower initial CD4 lymphocyte count. Conclusions: Antiretroviral adherence is not stable over time. Interventions aimed at monitoring and improving long-term adherence in women are urgently needed. (C) 2002 Lippincott Williams & Wilkins.
引用
收藏
页码:2175 / 2182
页数:8
相关论文
共 32 条
[1]   Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users [J].
Arnsten, JH ;
Demas, PA ;
Grant, RW ;
Gourevitch, MN ;
Farzodegan, H ;
Howard, AA ;
Schoenboum, EE .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (05) :377-381
[2]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[3]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[4]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[5]  
Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114
[6]  
Carrieri P, 2001, J ACQ IMMUN DEF SYND, V28, P232, DOI 10.1097/00042560-200111010-00005
[7]  
*CDCP, 1999, CDC UPDATE DEC, P1
[8]   Self-reported antiretroviral therapy in injection drug users [J].
Celentano, DD ;
Vlahov, D ;
Cohn, S ;
Shadle, VM ;
Obasanjo, O ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :544-546
[9]   Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine [J].
Collier, AC ;
Coombs, RW ;
Schoenfeld, DA ;
Bassett, RL ;
Timpone, J ;
Baruch, A ;
Jones, M ;
Facey, K ;
Whitacre, C ;
McAuliffe, VJ ;
Friedman, HM ;
Merigan, TC ;
Reichman, RC ;
Hooper, C ;
Corey, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1011-1017
[10]   ON WHITE-COAT EFFECTS AND THE ELECTRONIC MONITORING OF COMPLIANCE [J].
FEINSTEIN, AR .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (07) :1377-1378